Dave DeLucia

Former CEO and Co-Founder
ImmuNext

Dave, CEO, co-founded ImmuNext with Randy Noelle, CSO. ImmuNext developed immunomodulatory antibodies to the pre-clinical qualified lead stage and out-licensed them to Janssen, Roche, Eli Lilly and Sanofi. With just $500K from founders, $125K from angels and $15M in SBIR grants, ImmuNext generated >$500M of profit. The team was just 10-15 people of loyal staff.